Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial

Stephen J. Nicholls, Adam J. Nelson

Research output: Contribution to journalReview article

Abstract

The COMPASS trial compared the impact of the selective direct factor Xa inhibitor, rivaroxaban, as monotherapy or in combination with aspirin on major adverse cardiovascular events (MACE) in patients with stable atherosclerotic disease. Patients treated with rivaroxaban 2.5 mg twice daily in combination with aspirin experienced fewer cardiovascular events but more bleeding complications than those who received aspirin monotherapy. In contrast, a higher dose of rivaroxaban (5 mg twice daily) and aspirin produced no clinical benefit and continued to be associated with greater bleeding rates than aspirin. Examining this study in the context of other trials of anticoagulant therapy in atherosclerotic vascular disease, this review attempts to place the role of very low-dose rivaroxaban in clinical context and highlights areas for future research.

LanguageEnglish
Pages343-348
Number of pages6
JournalAmerican Journal of Cardiovascular Drugs
Volume19
Issue number4
DOIs
Publication statusPublished - 1 Aug 2019

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

@article{740eeeae68ad4ac59794bc7806ea1c40,
title = "Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial",
abstract = "The COMPASS trial compared the impact of the selective direct factor Xa inhibitor, rivaroxaban, as monotherapy or in combination with aspirin on major adverse cardiovascular events (MACE) in patients with stable atherosclerotic disease. Patients treated with rivaroxaban 2.5 mg twice daily in combination with aspirin experienced fewer cardiovascular events but more bleeding complications than those who received aspirin monotherapy. In contrast, a higher dose of rivaroxaban (5 mg twice daily) and aspirin produced no clinical benefit and continued to be associated with greater bleeding rates than aspirin. Examining this study in the context of other trials of anticoagulant therapy in atherosclerotic vascular disease, this review attempts to place the role of very low-dose rivaroxaban in clinical context and highlights areas for future research.",
author = "Nicholls, {Stephen J.} and Nelson, {Adam J.}",
year = "2019",
month = "8",
day = "1",
doi = "10.1007/s40256-018-00322-4",
language = "English",
volume = "19",
pages = "343--348",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "4",

}

Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease : Clinical Implications of the COMPASS Trial. / Nicholls, Stephen J.; Nelson, Adam J.

In: American Journal of Cardiovascular Drugs, Vol. 19, No. 4, 01.08.2019, p. 343-348.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease

T2 - American Journal of Cardiovascular Drugs

AU - Nicholls, Stephen J.

AU - Nelson, Adam J.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - The COMPASS trial compared the impact of the selective direct factor Xa inhibitor, rivaroxaban, as monotherapy or in combination with aspirin on major adverse cardiovascular events (MACE) in patients with stable atherosclerotic disease. Patients treated with rivaroxaban 2.5 mg twice daily in combination with aspirin experienced fewer cardiovascular events but more bleeding complications than those who received aspirin monotherapy. In contrast, a higher dose of rivaroxaban (5 mg twice daily) and aspirin produced no clinical benefit and continued to be associated with greater bleeding rates than aspirin. Examining this study in the context of other trials of anticoagulant therapy in atherosclerotic vascular disease, this review attempts to place the role of very low-dose rivaroxaban in clinical context and highlights areas for future research.

AB - The COMPASS trial compared the impact of the selective direct factor Xa inhibitor, rivaroxaban, as monotherapy or in combination with aspirin on major adverse cardiovascular events (MACE) in patients with stable atherosclerotic disease. Patients treated with rivaroxaban 2.5 mg twice daily in combination with aspirin experienced fewer cardiovascular events but more bleeding complications than those who received aspirin monotherapy. In contrast, a higher dose of rivaroxaban (5 mg twice daily) and aspirin produced no clinical benefit and continued to be associated with greater bleeding rates than aspirin. Examining this study in the context of other trials of anticoagulant therapy in atherosclerotic vascular disease, this review attempts to place the role of very low-dose rivaroxaban in clinical context and highlights areas for future research.

UR - http://www.scopus.com/inward/record.url?scp=85060644009&partnerID=8YFLogxK

U2 - 10.1007/s40256-018-00322-4

DO - 10.1007/s40256-018-00322-4

M3 - Review article

VL - 19

SP - 343

EP - 348

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 4

ER -